Welcome to the weekend news dump. The news dribbling out on a weekend is usually the stuff companies want to bury, and there’s been a couple of obvious stinkers…
Pharmaceuticals
Politics is a harsh mistress, but it gets considerably harsher when the ruling party decides to let anarchy reign because it suits their plans for reelection. Such was the…
Back when Vanc Pharmaceuticals (NPH.V) rolled out last year, a decent marketing push was resisted in many quarters by retail investors who just didn’t believe the business model. Here’s…
Cannabis research play Veritas Pharmaceuticals (VRT.C) announced news after yesterday’s close, as predicted here at Equity.Guru, and the news was most definitely good. If you’re in the cancer research…
Busy day prowling the halls of Vancouver’s brokers today, jamming CEO meetings from 8am through to a few minutes ago. Caught up with the crews from Health Space (HS.C)*,…
Had a long and detailed discussion last night with the very busy CEO of Veritas Pharma (VRT.C)*, Dr. Lui Franciosi, and came away pretty impressed with the man and his…
Great morning if you’ve been doing your due diligence through Equity Guru – some of our favourites have been jumping today by 20% or more. Nano One Materials* (NNO.V)…
Today marks the end of the first week of Equity Guru’s legit existence, and it’s been a beauty. First, we’ve signed enough sponsor deals to be liquid well into…
Regular readers (of my as yet un-launched site) will know I’ve been talking to Veritas Pharma (VRT.C) over the last few weeks. I’m liking the business more and more,…
Just kidding. Nothing can fix Valeant Pharmaceuticals (VRX.T). Canada’s Big Pharma Clown Car has been in an out of congressional committees wondering why it charges a small fortune for…